---
title: "5-Amino-1MQ"
canonical_url: https://peptidelibrary.app/library/5-amino-1mq
description: "Small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor studied for NAD+ metabolism and body-composition research. Not an FDA-approved drug."
updated: 2026-09-06
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# 5-Amino-1MQ

5-Amino-1MQ (also called 5-amino-1-methylquinolinium or NNMT inhibitor) is a small molecule in the NNMT Inhibitor class. 5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase, a cytosolic enzyme that transfers a methyl group from S-adenosylmethionine to nicotinamide, producing 1-methylnicotinamide. That reaction removes nicotinamide from the salvage pathway that regenerates NAD+, and it consumes methyl groups.

Small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor studied for NAD+ metabolism and body-composition research. Not an FDA-approved drug.

Also known as: 5-amino-1-methylquinolinium, NNMT inhibitor.

Categories: Fat Loss, GLP-1/Metabolic, Experimental.

## Classification

- Type: Small Molecule / Metabolic
- Mechanism class: NNMT Inhibitor
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase, a cytosolic enzyme that transfers a methyl group from S-adenosylmethionine to nicotinamide, producing 1-methylnicotinamide. That reaction removes nicotinamide from the salvage pathway that regenerates NAD+, and it consumes methyl groups. NNMT is highly expressed in white adipose tissue and liver and is upregulated in obesity. Inhibiting it is proposed to preserve the nicotinamide pool available for NAD+ synthesis and to alter adipocyte metabolism, and in rodent models NNMT knockdown or inhibition reduced fat mass and improved metabolic parameters on a high-fat diet. It is a small molecule rather than a peptide, and no human trials have been published.

Targets: NNMT, NAD+ salvage pathway.

Origin: Synthetic quinolinium small molecule; not a peptide.

## Properties

- Sequence: N/A (small-molecule NNMT inhibitor; not a peptide)
- Molecular formula: C10H11IN2
- Molecular weight: 286.11 g/mol
- CAS number: 42464-96-0
- Half-life: 3.8-6.9 hours

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: Lab & animal studies
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 1
- Latest source: 2024

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes Obes Metab. 2024. 2024. Preclinical: animal or lab study. Population: Diet-induced obese mice. Adipose mass and metabolic parameters. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/39161060/)

## Safety

Side effects: Limited human safety data; GI upset reported anecdotally; Unknown long-term effects.

Risks: Research-only; no approved human indication; Human outcome data are sparse.

Contraindications: Liver/kidney issues; Hypersensitivity.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

5-Amino-1MQ is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is 5-Amino-1MQ?

Small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor studied for NAD+ metabolism and body-composition research. Not an FDA-approved drug.

### How does 5-Amino-1MQ work?

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase, a cytosolic enzyme that transfers a methyl group from S-adenosylmethionine to nicotinamide, producing 1-methylnicotinamide. That reaction removes nicotinamide from the salvage pathway that regenerates NAD+, and it consumes methyl groups.

### Is 5-Amino-1MQ FDA approved?

No. 5-Amino-1MQ is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of 5-Amino-1MQ?

Reported half-life for 5-Amino-1MQ is 3.8-6.9 hours. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of 5-Amino-1MQ?

5-Amino-1MQ has the sequence N/A (small-molecule NNMT inhibitor; not a peptide), giving a chain of 2 amino acids. Its molecular formula is C10H11IN2.

### What peptides are similar to 5-Amino-1MQ?

Compounds most often compared with 5-Amino-1MQ include SLU-PP-332, BAM15, AICAR and Tesofensine. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [PubChem 5-Amino-1MQ](https://pubchem.ncbi.nlm.nih.gov/compound/5-Amino-1-methylquinolinium)
- [Emerging opportunities for nicotinamide N-methyltransferase (NNMT) inhibitor clinical translation — Trends Pharmacol Sci, 2026](https://pubmed.ncbi.nlm.nih.gov/42067476/)
- [Nicotinamide N-Methyltransferase (NNMT) and Liver Cancer: From Metabolic Networks to Therapeutic Targets — Biomolecules, 2025](https://pubmed.ncbi.nlm.nih.gov/40427612/)
- [Nicotinamide N-Methyltransferase: A Promising Biomarker and Target for Human Cancer Therapy — Front Oncol, 2022](https://pubmed.ncbi.nlm.nih.gov/35756670/)
- [Nicotinamide N-methyl transferase (NNMT): An emerging therapeutic target — Drug Discov Today, 2021](https://pubmed.ncbi.nlm.nih.gov/34029690/)
- [Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation — Mol Metab, 2021](https://pubmed.ncbi.nlm.nih.gov/33453420/)
